Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$115.92 USD

115.92
1,229,211

+2.42 (2.13%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $115.98 +0.06 (0.05%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Incyte (INCY) Initiates Essential Thrombocythemia Trial

by Zacks Equity Research

Incyte (INCY) announced that the first patient has been treated in the essential thrombocythemia trial on ruxolitinib. A potential label expansion of the drug will boost sales.

    Zacks Equity Research

    Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

    by Zacks Equity Research

    Roche's (RHHBY) diagnostic portfolio gets a further boost with FDA's clearance for Ventana tests.

      Zacks Equity Research

      Novartis (NVS) Arm's Biosimilars Study Results Encourage

      by Zacks Equity Research

      Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

        Zacks Equity Research

        Ligand (LGND) Q3 Earnings & Revenues Top, 2017 View Raised

        by Zacks Equity Research

        Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.

          Zacks Equity Research

          Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y

          by Zacks Equity Research

          Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.

            Zacks Equity Research

            Ophthotech (OPHT) Q3 Earnings & Sales Beat, Zimura in Focus

            by Zacks Equity Research

            Ophthotech (OPHT) reported better-than-expected third-quarter earnings and sales. The company continues to advance Zimura in several indications.

              Zacks Equity Research

              What's in Store for Ligand (LGND) This Earnings Season?

              by Zacks Equity Research

              Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.

                Zacks Equity Research

                Teva (TEVA) Stock Plunges 20% on Q3 Earnings Miss & View Cut

                by Zacks Equity Research

                Teva's (TEVA) third-quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.

                  Zacks Equity Research

                  Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

                  by Zacks Equity Research

                  Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

                    Zacks Equity Research

                    Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat

                    by Zacks Equity Research

                    Intercept's (ICPT) third-quarter results were encouraging as loss was narrower than expected while Ocaliva registered a sequential increase.

                      Arpita Dutt headshot

                      5 Biotech and Pharma Stocks with Key FDA Catalysts this November

                      by Arpita Dutt

                      Here is a look at five biotech and pharma stocks including Dynavax (DVAX) that have an important regulatory event lined up this month.

                        Zacks Equity Research

                        Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

                        by Zacks Equity Research

                        Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

                          Zacks Equity Research

                          Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss

                          by Zacks Equity Research

                          Aduro BioTech's (ADRO) third-quarter results were unimpressive with the company reporting loss as expected and revenues missing estimates.

                            Zacks Equity Research

                            Novartis Buys French Radiopharmaceutical Company

                            by Zacks Equity Research

                            Novartis (NVS) plans to acquire France-based Advanced Accelerator Applications. The takeover will add RadioLigand Therapy, Lutathera, in its portfolio with potential to drive growth in the near term.

                              Zacks Equity Research

                              Advanced Accelerator (AAAP) in Focus: Stock Moves 10.4% Higher

                              by Zacks Equity Research

                              Advanced Accelerator (AAAP) was a big mover last session, as the company saw its shares more than 10% on the day amid huge volumes.

                                Zacks Equity Research

                                What's in Store for Juno Therapeutics (JUNO) in Q3 Earnings?

                                by Zacks Equity Research

                                Although Juno Therapeutics' (JUNO) product portfolio shows a dearth of any revenue figures, the company's most advanced pipeline candidates -- JCAR017 and JCAR014 -- might drive its progress in Q3.

                                  Swarup Gupta headshot

                                  Foreign Stock Roundup: Novartis, Bayer, Glaxo, Total Beat on Earnings

                                  by Swarup Gupta

                                  Political developments guided the movement of most non U.S. markets this week.

                                    Zacks Equity Research

                                    What's in Store for Conatus (CNAT) This Earnings Season?

                                    by Zacks Equity Research

                                    Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.

                                      Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Visa, Coca-Cola, United Technologies, AT&T and Novartis

                                        Zacks Equity Research

                                        Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                                        by Zacks Equity Research

                                        The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.

                                          Zacks Equity Research

                                          Amgen (AMGN) Q3 Earnings Top, Sales Decline Y/Y, Stock Falls

                                          by Zacks Equity Research

                                          Though Amgen (AMGN) beat estimates on both earnings & sales and raised its earnings outlook, shares declined in after-hours trading due to the year-over-year decline in revenues.

                                            Zacks Equity Research

                                            Drug Stock Q3 Earnings Roster for Oct 26: GILD, BMY & More

                                            by Zacks Equity Research

                                            Four major biotech giants are set to report third-quarter results on Oct 26. A sneak preview as to how things are shaping up for these companies.

                                              Zacks Equity Research

                                              Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength

                                              by Zacks Equity Research

                                              Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.

                                                Zacks Equity Research

                                                Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX

                                                by Zacks Equity Research

                                                The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.

                                                  Arpita Dutt headshot

                                                  Gilead Drug Approval Fuels Interest in CAR-T Space: 3 Stocks to Consider

                                                  by Arpita Dutt

                                                  Will the FDA approval of Novartis and Gilead's (GILD) CAR-T cell therapies fuel more partnership deals and acquisitions in this space?